Navigation Links
CeNeRx BioPharma Completes $4.85 Million Financing
Date:12/9/2011

RESEARCH TRIANGLE PARK, N.C., Dec. 9, 2011 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $4.85 million financing.  Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners, Pappas Ventures and Omega Funds all participated in the financing.  CeNeRx plans to use the proceeds to complete its ongoing Phase II trial of the improved formulation of its novel antidepressant TriRima™ as monotherapy in treatment resistant depression, as well as to support advancement of its pipeline of promising agents for a variety of CNS disorders.

"Our Phase II trial of TriRima in treatment resistant depression is proceeding very well and these funds will primarily be used to help complete the study," said Barry Brand, Chief Executive Officer of CeNeRx.  "The pace of enrollment has been excellent – we have enrolled almost 80% of the 360 patients targeted for this trial and hope to complete the study and report headline data by mid-2012." 

Treatment resistant depression represents a large and serious problem, with between 30-50% of depressed patients not responding to traditional antidepressant therapy.  The only FDA-approved medications for treatment resistant depression are atypical antipsychotics, which are associated with significant safety concerns such as tardive dyskinesia, metabolic syndrome, hypoglycemia and diabetes.  TriRima has the opportunity to fill this therapeutic gap and to be the first monotherapy for treatment resistant depression that avoids the safety issues of the atypical antipsychotics. 

Mr. Brand continued, "As expected, thus far in this Phase II trial we have seen no signs of the food-associated hypertensive effects of conventional MAO inhibitors.  In addition, blinded assays of the subjects i
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Publication in Neuropsychopharmacology Confirms CeNeRxs Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
2. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
3. CeNeRx BioPharma Completes $15 Million Series B Financing
4. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Windhover Announces the "Top Biopharma Projects to Watch"
7. Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
8. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
9. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
10. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
11. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Mass. , June 2, 2015  Alere ... in rapid diagnostics, joined the White House Antibiotic ... of commitments to support and advance the President,s ... Company,s commitments include a number of measurable goals ... when achieved, will help healthcare providers protect their ...
(Date:6/2/2015)... June 02, 2015 Through rare discovery ... Yancy Corporation is enabling World Scientists to ... and biological sample, displaying the full nature (position, shape, ... atoms. , Jeff Porter, Co-Founder of the Yancy Corporation, ... that – rare. They come once in a lifetime, ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 German-based Moenninghoff ... United States distributor for the Moenninghoff product line ... “I am pleased to announce that the R.M. Hoffman ... For our firm, founded in 1916, this is a ... Hoffman is the kind of professional distributor we need ...
(Date:6/1/2015)... 2015 Chosen for his engaging ... Uldrich has been selected as keynote speaker for ... He will deliver his keynote: "Don't Stop Thinking ... presentations to the American Medical Association, Blue Cross ... Alcetel-Lucent/Verizon Forum on Wireless Healthcare, United Healthcare, IASIS ...
Breaking Biology Technology:Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2
... Live On Company,s Website -, TUSTIN, Calif., Oct. ... clinical stage biopharmaceutical,company developing monoclonal antibodies for the treatment ... management will,present at the BIO Investor Forum 2008 on ... EDT). The conference will be held at the Palace ...
... 28 Neurocrine Biosciences,(Nasdaq: NBIX ) announces the following Webcast:, ... When: October 28, 2008 @ 5 p.m. Eastern ... How: Live over the Internet -- Simply log ... above., Contact: Claudia Woodworth, 858-617-7759 ...
... MEMY ) today announced that it has received,notice ... of the,Company,s common stock will be transferred from The ... the opening of trading on October,28, 2008. The Company,s ... The Panel has also notified the Company that it ...
Cached Biology Technology:Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008 2Memory Pharmaceuticals Provides Update on NASDAQ Listing Status 2Memory Pharmaceuticals Provides Update on NASDAQ Listing Status 3
(Date:6/1/2015)... According to a new market research report ... & Touchless), Application (Consumer Electronics, Automotive, & Others), Product ... Forecast to 2020", published by MarketsandMarkets, the Gesture Recognition ... Billion by 2020, at a CAGR of 28.23% between ... data T ables and   86   F ...
(Date:6/1/2015)... 1, 2015 According to ... Market by Application (Government, Military & Defense, Healthcare, ... and Security), Technology (Face Recognition, Fingerprint Recognition, Iris ... Recognition, and Others), Function (Contact and Non-Contact) & ... Europe , APAC, Row) - Global ...
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... with a common condition that causes frequent nighttime ... minimally invasive treatment that shrinks the prostate, suggests a ... 38th Annual Scientific Meeting in New Orleans. The early ... prostatic artery embolization (PAE), which reduces blood flow to ...
... Inc. (OTC Markets: MDBX) ( www.medboxinc.com ), a leader ... to various medical and retail related industries worldwide, seeks ... in the mushrooming legal marijuana industry and has issued a ... past, present, and future projects. Company CEO, ...
... sea levels, new research indicates that cutting emissions of ... this century. The research team found that reductions ... atmosphere could temporarily forestall the rate of sea level ... avoid potentially dangerous sea level rise, we could cut ...
Cached Biology News:Nonsurgical treatment turns back the clock, shrinks enlarged prostate 2Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 2Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 3Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 4Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry 5Cutting specific pollutants would slow sea level rise 2Cutting specific pollutants would slow sea level rise 3
Anti-Human Factor XI Purified (Polyclonal) (sheep IgG)...
...
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Biology Products: